CASPR Biotech

Next-generation CRISPR diagnostics

CASPR Biotech operates in diagnostics based in United States, founded in 2018.

Profile

Caspr.bio has a COVID-19 test leveraging the CRISPR Cas-12 enzyme that is cheap and rapid, at point of care. The San Francisco and Buenos Aires-based company started 2 years ago, went through IndieBio, and originally worked on Zika virus and other genetic testing. Caspr’s methodology delivers positive tests results very quickly after RNA extraction (1 hour vs. 8+ hours or days in some instances), using devices that cost less than $200 and testing strips that cost less than $10. Because the tests do not require a lab to process, they can be administered in public places such as train stations, business lobbies and airports. Once approved by the FDA, Caspr’s test will be the first CRISPR-approved COVID-19 diagnostic test. The company has working prototypes, plans to scale production over the next 2 months and start commercial testing at hospitals and labs in New York soon. Interview with Franco Goytia of CASPR Biotech (YouTube)

As a business in diagnostics, CASPR Biotech is listed here with the public details available about it.

The business is associated with United States.

The company is listed at the SOSV portfolio company stage of development.

The company reports a headcount in the 2-10 range.

It has disclosed roughly $4K in funding.

Website: caspr.bio